Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (3433)	6/23/1998 10:13:00 PM
From: Peter V	Read Replies (2) \| Respond to of 5736

Janybird, Maisels admitted he is no expert on markets. Just because Unicef indicates that there are babies that are going to be born, does not mean that the BiliTest is going to be used on them, especially if it is more expensive than current methods. His estimation of the market based on the number of babies born does not account for the one fundamental crux of the entire market isssue: the potential penetration of the BiliTest into the market occupied by already existing testing methods. Without that analysis, Maisels opinion on the potential market is worthless. Look at what he says: I cannot claim expertise in how "markets" are calculated, but the potential for the use of transcutaneous bilirubinometry involves the majority of babies born in the world. . . . This does not strike me as being an "extremely limited" market." It is clear that this is an opinion, not based on any analysis of the potential market penetratin of the device. You can believe him if you want, but Maisels is not an expert in this area. Moreover, he is an interested party that owns a large number of shares in CCSI, and thus has a vested interest in its stock price. I'd be more inclined to believe a completely neutral third party, not someone that CCSI has paid to test and endorse its device, and who expresses opinions in an area in which he is not qualified.

To: JanyBlueEyes who wrote (3433)	6/23/1998 10:41:00 PM
From: Steve	Read Replies (2) \| Respond to of 5736

"Thus the use of noninvasive bilirubin determinations will not be restricted to the hospital, will likely find as much or more use in the outpatient population. As there are 132,418,000 babies born annually throughout the world (1996 data from UNICEF) it is reasonable to assume that about 90% or 119,176,200 annually will be potential subjects for a bilirubin determination. This does not strike me as being an "extremely limited" market."" Janybird: If this device is such a big deal how did the world ever survive for so many years without it. How many people have come to you and said there newborn baby died of jaundice? I may not know much about investing, if I did I would have shorted this at $15 a share, but since I am a doctor I do know medicine and I'm telling you this device is worthless. Call your pediatrician and ask them if they think every mother needs a TLc-BiliTest at home. I don't want to pick a fight with you here but you really should contact some hospitals and other doctors and see if they think this device will fly regardless of what Dr. Maisels says.